t(14;18) translocation: A predictive blood biomarker for follicular lymphoma

Journal of Clinical Oncology

Volumn 32, Issue 13, 2014, Pages 1347-1355

  Roulland, Sandrine ^a   Kelly, Rachel S ^g   Morgado, Ester ^a   Sungalee, Stéphanie ^a   Solal Celigny, Philippe ^b   Colombat, Philippe ^c   Jouve, Nathalie ^a   Palli, Domenico ^k   Pala, Valeria ^l   Tumino, Rosario ^m   Panico, Salvatore ⁿ   Sacerdote, Carlotta ^o   Quirós, José R ^p   Gonzáles, Carlos A ^q   Sánchez, Maria José ^r   Dorronsoro, Miren ^s   Navarro, Carmen ^t   Barricarte, Aurelio ^u   Tjønneland, Anne ^v   Olsen, Anja ^v   Overvad, Kim ^w   Canzian, Federico ^x   Kaaks, Rudolf ^x   Boeing, Heiner ^y   Drogan, Dagmar ^y   Nieters, Alexandra ^z   Clavel Chapelon, Françoise ^d   Trichopoulou, Antonia ^aa,ab   Trichopoulos, Dimitrios ^aa,ab,ad   Lagiou, Pagona ^aa,ac,ad   Bueno de Mesquita, H Bas ^ae,af   Peeters, Petra H M ^g,af   Vermeulen, Roel ^g,af   Hallmans, Göran ^ag   Melin, Beatrice ^ag   Borgquist, Signe ^ah   Carlson, Joyce ^ah   Lund, Eiliv ^aj   Weiderpass, Elisabete ^ai,aj,ak,al   Khaw, Kay Tee ^h   Wareham, Nick ⁱ   Key, Timothy J ^j   Travis, Ruth C ^j   Ferrari, Pietro ^e   Romieu, Isabelle ^e   Riboli, Elio ^g   Salles, Gilles ^f   Vineis, Paolo ^g   Nadel, Bertrand ^a   more..

^a INSERM   (France)

^b Jean Bernard Center   (France)

^c CHU BRETONNEAU   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f UNIVERSITÉ DE LYON   (France)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k Istituto per lo Studio e la Prevenzione Oncologica   (Italy)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m CIVILE M P AREZZO HOSPITAL   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica   (Italy)

^p Public Health and Health Planning Directorate   (Italy)

^q CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^r CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^s BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^t DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^u INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^v DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^w AARHUS UNIVERSITY   (Denmark)

^x GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^y GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^z UNIVERSITY OF FREIBURG   (Germany)

^aa UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^ab HELLENIC HEALTH FOUNDATION   (Greece)

^ac BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^ad HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^ae NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^af UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ag UMEÅ UNIVERSITY   (Sweden)

^ah LUND UNIVERSITY   (Sweden)

^ai KAROLINSKA INSTITUTE   (Sweden)

^aj UNIVERSITY OF TROMSØ   (Norway)

^ak CANCER REGISTRY OF NORWAY   (Norway)

^al FOLKHÄLSAN RESEARCH CENTER   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN BCL 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENE TRANSLOCATION; GENETIC RISK; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT; T(14;18) TRANSLOCATION; BLOOD; CASE CONTROL STUDY; CHROMOSOME 14; CHROMOSOME 18; EUROPE; GENETICS; METHODOLOGY; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PREVALENCE;

ADULT; AGED; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; COHORT STUDIES; EUROPE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; POLYMERASE CHAIN REACTION; PREVALENCE; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84902684758     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.8190     Document Type: Article

References (54)

1. Montoto S, Fitzgibbon J: Transformation of indolent B-cell lymphomas. J Clin Oncol 29:1827-1834, 2011
2. Relander T, Johnson NA, Farinha P, et al: Prognostic factors in follicular lymphoma. J Clin Oncol 28:2902-2913, 2010
3. Shaffer AL 3rd, Young RM, Staudt LM: Pathogenesis of human B cell lymphomas. Annu Rev Immunol 30:565-610, 2012
4. Kridel R, Sehn LH, Gascoyne RD: Pathogenesis of follicular lymphoma. J Clin Invest 122:3424-3431, 2012
5. Limpens J, Stad R, Vos C, et al: Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 85:2528-2536, 1995
6. Dölken G, Illerhaus G, Hirt C, et al: BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 14:1333-1344, 1996
7. Schüler F, Dölken L, Hirt C, et al: Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. Int J Cancer 124:958-963, 2009
8. Roulland S, Faroudi M, Mamessier E, et al: Early steps of follicular lymphoma pathogenesis. Adv Immunol 111:1-46, 2011
9. Bretherick KL, Bu R, Gascoyne RD, et al: Elevated circulating t(14;18) translocation levels prior to diagnosis of follicular lymphoma. Blood 116:6146-6147, 2010
10. Hart J, Turner AR, Larratt L, et al: Transmission of a follicular lymphoma by allogeneic bone marrow transplantation: Evidence to support the existence of lymphoma progenitor cells. Br J Haematol 136:166-167, 2007 (Pubitemid 44912606)
11. Weigert O, Kopp N, Lane AA, et al: Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov 2:47-55, 2012
12. Roulland S, Navarro JM, Grenot P, et al: Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J Exp Med 203:2425-2431, 2006 (Pubitemid 44664612)
13. Hirt C, Dölken G, Janz S, et al: Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals. Br J Haematol 138:349-353, 2007 (Pubitemid 47035397)
14. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single firstline therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001 (Pubitemid 32061248)
15. Brice P, Bastion Y, Lepage E, et al: Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires - Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 15:1110-1117, 1997 (Pubitemid 27106296)
16. Søreide K: Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol 62:1-5, 2009
17. Riboli E, Hunt KJ, Slimani N, et al: European Prospective Investigation Into Cancer and Nutrition (EPIC): Study populations and data collection. Public Health Nutr 5:1113-1124, 2002 (Pubitemid 36313608)
18. Buchonnet G, Jardin F, Jean N, et al: Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: Specific subtypes or same disease? Leukemia 16:1852-1856, 2002
19. Leich E, Salaverria I, Bea S, et al: Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 114:826-834, 2009
20. Roulland S, Lebailly P, Lecluse Y, et al: Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals. Leukemia 20:158-162, 2006
21. Landgren O, Albitar M, Ma W, et al: B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 360:659-667, 2009
22. Weiss BM, Abadie J, Verma P, et al: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418-5422, 2009
23. Landgren O, Kyle RA, Pfeiffer RM, et al: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood 113:5412-5417, 2009
24. Ware JH: The limitations of risk factors as prognostic tools. N Engl J Med 355:2615-2617, 2006
25. Elmore JG, Fletcher SW: The risk of cancer risk prediction: "What is my risk of getting breast cancer"? J Natl Cancer Inst 98:1673-1675, 2006 (Pubitemid 44942705)
26. Rawstron AC, Bennett FL, O'Connor SJ, et al: Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 359:575-583, 2008
27. Shanafelt TD, Kay NE, Rabe KG, et al: Brief report: Natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 27:3959-3963, 2009
28. Shanafelt TD, Ghia P, Lanasa MC, et al: Monoclonal B-cell lymphocytosis (MBL): Biology, natural history and clinical management. Leukemia 24:512-520, 2010
29. Korde N, Kristinsson SY, Landgren O: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies. Blood 117:5573-5581, 2011
30. Fazi C, Scarfò L, Pecciarini L, et al: General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 118:6618-6625, 2011
31. Vardi A, Dagklis A, Scarfò L, et al: Immunogenetics shows that not all MBL are equal: The larger the clone, the more similar to CLL. Blood 121:4521-4528, 2013
32. Dhodapkar MV, Sexton R, Waheed S, et al: Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85, 2014
33. Mateos MV, Hernández MT, Giraldo P, et al: Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 369:438-447, 2013
34. Barlogie B, van Rhee F, Shaughnessy JD Jr, et al: Seven-year median time to progression with thalidomide for smoldering myeloma: Partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112:3122-3125, 2008
35. Fisher SG, Fisher RI: The epidemiology of non-Hodgkin's lymphoma. Oncogene 23:6524-6534, 2004 (Pubitemid 39265515)
36. Landgren O, Goedert JJ, Rabkin CS, et al: Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 28:773-779, 2010
37. Chiu BC, Dave BJ, Blair A, et al: Agricultural pesticide use and risk of t(14;18)-defined subtypes of non-Hodgkin lymphoma. Blood 108:1363-1369, 2006 (Pubitemid 44232037)
38. Giannelli F, Moscarella S, Giannini C, et al: Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 102:1196-1201, 2003 (Pubitemid 36988022)
39. Conde L, Halperin E, Akers NK, et al: Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 42:661-664, 2010
40. Mandigers CM, Meijerink JP, Mensink EJ, et al: Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 98:940-944, 2001
41. Drillenburg P, Pals ST: Cell adhesion receptors in lymphoma dissemination. Blood 95:1900-1910, 2000 (Pubitemid 30151624)
42. Kiaii S, Clear AJ, Ramsay AG, et al: Follicular lymphoma cells induce changes in T-cell gene expression and function: Potential impact on survival and risk of transformation. J Clin Oncol 31:2654-2661, 2013
43. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004 (Pubitemid 39507628)
44. Schuster SJ, Neelapu SS, Santos CF, et al: Idiotype vaccination as consolidation therapy: Time for integration into standard of care for follicular lymphoma? J Clin Oncol 29:4845-4846, 2011
45. Fowler N, Neelapu S, Hagemeister F, et al: Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase II study. Blood, 2012 (abstr 901)
46. Carlotti E, Wrench D, Matthews J, et al: Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood 113:3553-3557, 2009
47. Ruminy P, Jardin F, Picquenot JM, et al: S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: Early direct or late from FL progenitor cells. Blood 112:1951-1959, 2008
48. Green MR, Gentles AJ, Nair RV, et al: Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121:1604-1611, 2013
49. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al: Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471:189-195, 2011
50. Morin RD, Johnson NA, Severson TM, et al: Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinalcenter origin. Nat Genet 42:181-185, 2010
51. Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298-303, 2011
52. Bödör C, Grossmann V, Popov N, et al: EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 122:3165-3168, 2013
53. Landau DA, Carter SL, Stojanov P, et al: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-726, 2013
54. Harismendy O, Schwab RB, Bao L, et al: Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol 12:R124, 2011